公开(公告)号：US20160235716A1

公开(公告)日：2016-08-18

申请号：US14857419

申请日：2015-09-17

Applicant: ABBVIE INC.

Inventor： Edward A. Kesicki ,  Arthur F. Kluge ,  Michael A. Patane ,  John H. Van Drie, JR. ,  Ce Wang ,  Maricel Torrent ,  Michael L. Curtin ,  Todd M. Hansen ,  Rick F. Clark ,  Robin R. Frey ,  Zhiqin Ji ,  Yujia Dai ,  William J. McClellan ,  Jane Gong ,  Gui-dong G. Zhu ,  Anthony Mastracchio ,  Michael R. Michaelides ,  Thomas D. Penning ,  Chunqiu C. Lai

IPC: A61K31/4184 ,  C07D403/06 ,  C07D405/06 ,  A61K31/423 ,  C07D401/06 ,  A61K31/4439 ,  C07D263/52 ,  C07D235/02 ,  C07D409/06

CPC classification number: A61K31/4184 ,  A61K31/423 ,  A61K31/4439 ,  C07D235/02 ,  C07D263/52 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D407/12 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D491/107 ,  C07D493/10 ,  C07D495/10 ,  C07D498/10

Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1- - - -Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

Abstract translation: 具有式（IX​​）结构的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中R1，R2a，R2b，R3a，R3b，R4a，R4b，Q1- - -Q2，R6，R7，A，B ，W，x和y如本文所定义并提供。 还提供了包含这些化合物的药物组合物和通过施用这些化合物治疗各种HAT相关病症或疾病（包括癌症）的方法。

公开(公告)号：US20180071262A1

公开(公告)日：2018-03-15

申请号：US15727220

申请日：2017-10-06

Applicant: AbbVie Inc.

Inventor： Edward A. Kesicki ,  Arthur F. Kluge ,  Michael A. Patane ,  John H. Van Drie, JR. ,  Ce Wang ,  Maricel Torrent ,  Michael L. Curtin ,  Todd M. Hansen ,  Rick F. Clark ,  Robin R. Frey ,  Zhiqin Ji ,  Yujia Dai ,  William J. McClellan ,  Jane Gong ,  Gui-dong G. Zhu ,  Anthony Mastracchio ,  Michael R. Michaelides ,  Thomas D. Penning ,  Chunqiu C. Lai

IPC: A61K31/4184 ,  C07D498/10 ,  C07D403/06 ,  C07D493/10 ,  C07D491/107 ,  C07D263/52 ,  C07D417/12 ,  C07D417/04 ,  C07D413/12 ,  C07D413/04 ,  C07D409/12 ,  C07D407/12 ,  C07D401/12 ,  C07D235/02 ,  C07D413/14 ,  C07D403/12 ,  C07D409/06 ,  C07D405/06 ,  A61K31/423 ,  A61K31/4439 ,  C07D401/06 ,  C07D495/10

CPC classification number: A61K31/4184 ,  A61K31/423 ,  A61K31/4439 ,  C07D235/02 ,  C07D263/52 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D407/12 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D491/107 ,  C07D493/10 ,  C07D495/10 ,  C07D498/10

Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

公开(公告)号：US20180193315A1

公开(公告)日：2018-07-12

申请号：US15907597

申请日：2018-02-28

Applicant: AbbVie Inc.

Inventor： Edward A. Kesicki ,  Arthur F. Kluge ,  Michael A. Patane ,  John H. Van Drie, JR. ,  Ce Wang ,  Maricel Torrent ,  Michael L. Curtin ,  Todd M. Hansen ,  Rick F. Clark ,  Robin R. Frey ,  Zhiqin Ji ,  Yujia Dai ,  William J. McClellan ,  Jane Gong ,  Gui-dong G. Zhu ,  Anthony Mastracchio ,  Michael R. Michaelides ,  Thomas D. Penning ,  Chunqiu C. Lai

IPC: A61K31/4184 ,  C07D403/06 ,  C07D498/10 ,  A61K31/4439 ,  A61K31/423 ,  C07D405/06 ,  C07D409/06 ,  C07D403/12 ,  C07D413/14 ,  C07D235/02 ,  C07D401/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D263/52 ,  C07D491/107 ,  C07D493/10 ,  C07D495/10 ,  C07D401/06

CPC classification number: A61K31/4184 ,  A61K31/423 ,  A61K31/4439 ,  C07D235/02 ,  C07D263/52 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D407/12 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D491/107 ,  C07D493/10 ,  C07D495/10 ,  C07D498/10

Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

公开(公告)号：US09388180B2

公开(公告)日：2016-07-12

申请号：US14029142

申请日：2013-09-17

Applicant: Abbott GmbH & Co. KG ,  AbbVie Inc.

Inventor： Hervé Geneste ,  Michael Ochse ,  Karla Drescher ,  Clarissa Jakob ,  Maricel Torrent

IPC: C07D491/14 ,  C07D495/14 ,  C07D498/14 ,  C07D513/14 ,  A61K31/4985 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P3/04 ,  C07D471/14 ,  C07D491/04 ,  C07D495/04 ,  C07D498/04

CPC classification number: C07D471/14 ,  A61K31/4985 ,  C07D491/04 ,  C07D491/14 ,  C07D495/04 ,  C07D495/14 ,  C07D498/04 ,  C07D498/14 ,  C07D513/14

Abstract: The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X, Y, Q1, Q2 have the following meanings: X is C—R3 or N; Q1 is S or O and Q2 is C—R4 or N and Q2 is connected to X via a double bond while Q1 is connected to X via a single bond; or Q2 is S or O and Q1 is C—R4 or N and Q1 is connected to X via a double bond while Q2 is connected to X via a single bond; Y is C—R5 or N; where in formula I the variables R1, R2, R3, R4 and R5 are as defined in the claims The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

Abstract translation: 本发明涉及式I化合物，N-氧化物，互变异构体，前药及其药学上可接受的盐。 在式I中，变量X，Y，Q1，Q2具有以下含义：X为C-R3或N; Q1是S或O，Q2是C-R4或N，Q2通过双键连接到X，而Q1通过单键连接到X; 或Q2是S或O，Q1是C-R4或N，并且Q1通过双键连接到X，而Q2通过单键连接到X; Y为C-R5或N; 在式I中，变量R1，R2，R3，R4和R5如权利要求中所定义。式I化合物，N-氧化物，互变异构体，其前药和药学上可接受的盐是磷酸二酯酶10A型和 用于制造药物并因此适合于治疗或控制选自神经系统疾病和精神疾病的医学病症，用于改善与此类疾病相关的症状并降低此类疾病的风险。